Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCohen, S.en
dc.contributor.authorProudman, S.en
dc.contributor.authorKivitz, A.en
dc.contributor.authorBurch, F.en
dc.contributor.authorDonohue, J.en
dc.contributor.authorBurstein, D.en
dc.contributor.authorSun, Y.en
dc.contributor.authorBanfield, C.en
dc.contributor.authorVincent, M.en
dc.contributor.authorNi, L.en
dc.contributor.authorZack, D.en
dc.identifier.citationArthritis Research and Therapy, 2011; 13(4):R125-1-R125-12en
dc.description.abstractINTRODUCTION: AMG 108 is a fully human, immunoglobulin subclass G2 (IgG2) monoclonal antibody that binds the human interleukin-1 (IL-1) receptor type 1, inhibiting the activity of IL-1a and IL-1b. In preclinical studies, IL-1 inhibition was shown to be beneficial in models of osteoarthritis (OA). The purpose of this two-part study was to evaluate the safety and pharmacokinetics (PK; Part A) and clinical effect (Part B) of AMG 108 in a double-blind, placebo-controlled, multiple-dose study in patients with OA of the knee. METHODS: In Part A, patients received placebo or AMG 108 subcutaneously (SC; 75 mg or 300 mg) or intravenously (IV; 100 mg or 300 mg) once every 4 weeks for 12 weeks; in Part B, patients received placebo or 300 mg AMG 108 SC, once every 4 weeks for 12 weeks. The clinical effect of AMG 108 was measured in Part B by using the Western Ontario and McMaster Universities (WOMAC) osteoarthritis index pain score. RESULTS: In Part A, 68 patients were randomized, and 64 received investigational product. In Part B, 160 patients were randomized, and 159 received investigational product. AMG 108 was well tolerated. Most adverse events (AEs), infectious AEs, serious AEs and infections, as well as withdrawals from the study due to AEs occurred at similar rates in both active and placebo groups. One death was reported in an 80-year-old patient (Part A, 300 mg IV AMG 108; due to complications of lobar pneumonia). AMG 108 serum concentration-time profiles exhibited nonlinear PK. The AMG 108 group in Part B had statistically insignificant but numerically greater improvement in pain compared with the placebo group, as shown by the WOMAC pain scores (median change, -63.0 versus -37.0, respectively). CONCLUSIONS: The safety profile of AMG 108 SC and IV was comparable with placebo in patients with OA of the knee. Patients who received AMG 108 showed statistically insignificant but numerically greater improvements in pain; however, minimal, if any, clinical benefit was observed. TRIAL REGISTRATION: This study is registered with with the identifier NCT00110942.en
dc.description.statementofresponsibilityStanley B Cohen, Susanna Proudman, Alan J Kivitz, Francis X Burch, John P Donohue, Deborah Burstein, Yu-Nien Sun, Christopher Banfield, Michael S Vincent, Liyun Ni, and Debra J Zacken
dc.publisherBioMed Centralen
dc.rights© 2011 Cohen et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.en
dc.subjectHumans; Osteoarthritis, Knee; Pain; Receptors, Interleukin-1; Antirheumatic Agents; Antibodies, Monoclonal; Infusions, Intravenous; Injections, Subcutaneous; Double-Blind Method; Dose-Response Relationship, Drug; Middle Aged; Female; Maleen
dc.titleA randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the kneeen
dc.typeJournal articleen
pubs.library.collectionMedicine publicationsen
dc.identifier.orcidProudman, S. [0000-0002-3046-9884]en
Appears in Collections:Medicine publications

Files in This Item:
File Description SizeFormat 
hdl_88984.pdfPublished version427.75 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.